vimseltinib dihydrate

{
  "id": "MLC-T-ONC-009237",
  "term": "vimseltinib dihydrate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with tenosynovial giant cell tumor, a rare, usually benign (not cancer) tumor that affects the joints. It is used when surgery may make the symptoms worse or cause severe problems. It is also being studied in the treatment of other conditions related to cancer. Vimseltinib dihydrate blocks certain proteins, which may help keep tumor cells from growing and spreading. It is a type of tyrosine kinase inhibitor. Also called Romvimza.",
    "An orally bioavailable inhibitor of the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), with potential antineoplastic, macrophage checkpoint-inhibitory and immunomodulating activities. Upon administration, vimseltinib targets and binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment (TME) and activity of CSF1R-dependent tumor-associated macrophages (TAMs), vimseltinib inhibits the immunomodulating activity by macrophages and enhances T-cell infiltration and anti-tumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in the TME and allow for immune suppression; TAMs promote inflammation, tumor cell proliferation, angiogenesis, invasiveness and survival."
  ],
  "synonyms": [
    "Romvimza",
    "CSF-1R inhibitor DCC-3014"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/vimseltinib-dihydrate/"
}